公开(公告)号：WO2017059281A1

公开(公告)日：2017-04-06

申请号：PCT/US2016/054842

申请日：2016-09-30

Applicant: MCQUILLAN, Sharon, Patrica

Inventor： MCQUILLAN, Sharon, Patrica

IPC: A61K35/12 ,  A61N7/00 ,  C12N13/00

CPC classification number: A61L27/3687 ,  A61K31/00 ,  A61K35/19 ,  A61K35/28 ,  A61K35/35 ,  A61L27/3604 ,  A61L27/3616 ,  A61L27/3645 ,  A61L27/3834 ,  A61L27/50 ,  A61L27/54 ,  A61L2300/412 ,  A61L2300/64 ,  A61L2400/06 ,  A61M1/0068 ,  A61M1/008 ,  A61M1/0094 ,  A61M2202/08 ,  C12N5/0667 ,  C12N9/22 ,  C12Y301/21001 ,  A61K2300/00

Abstract: The present invention discloses adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF), their compositions and kits containing the ADSC's and their enriched fractions, and enzyme blends useful for their isolation, as well as methods of their isolation and use.

Abstract translation: 本发明公开了脂肪来源的干细胞（ADSC），脂肪来源的干细胞富集的部分（ADSC-EF），它们的组合物和含有ADSC及其富集部分的试剂盒，以及用于其分离的酶混合物，以及 隔离和使用的方法。

公开(公告)号：WO2016040169A3

公开(公告)日：2016-05-26

申请号：PCT/US2015048606

申请日：2015-09-04

Applicant: BURNS BARRY

Inventor： BURNS BARRY

IPC: A61K31/185 ,  A61K9/00 ,  A61K31/198 ,  A61K38/46 ,  A61P11/12

CPC classification number: A61K38/465 ,  A61K9/0078 ,  A61K31/10 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K45/06 ,  C12Y301/21001 ,  A61K2300/00

Abstract: Mucolytic agents for use in treating pulmonary sarcoidosis are described herein. Patients in need of treatment for pulmonary sarcoidosis are administered a therapeutically effective amount of a mucolytic agent such as DNase I, Mesna or DiMesna. In some embodiments, the DNase I is a recombinant human DNase I such as dornase alfa.

Abstract translation: 本文描述了用于治疗肺结节病的粘液溶解剂。 给予需要治疗肺结节病的患者施用治疗有效量的粘液溶解剂，例如DNase I，Mesna或DiMesna。 在一些实施方案中，DNA酶I是重组人类DNA酶I，例如转化酶α。

公开(公告)号：WO2015185534A1

公开(公告)日：2015-12-10

申请号：PCT/EP2015/062222

申请日：2015-06-02

Applicant: THERMO FISHER SCIENTIFIC BALTICS UAB

Inventor： ALZBUTAS, Gediminas ,  LAGUNAVIČIUS, Arūnas ,  KANIUŠAITĖ, Milda

IPC: C07K14/435

CPC classification number: C12N9/22 ,  C12Y301/21001

Abstract: Provided is a deoxyribonuclease comprising: (a) an amino acid sequence having at least 85% sequence identity with the sequence of a eukaryotic DNase I; and (b) an amino acid sequence capable of binding nucleic acid non-specifically comprising at least one helix-hairpin-helix motif.

Abstract translation: 提供了一种脱氧核糖核酸酶，其包含：（a）与真核生物DNA酶I的序列具有至少85％的序列同一性的氨基酸序列; 和（b）能够结合非特异性包含至少一个螺旋 - 发夹 - 螺旋基序的核酸的氨基酸序列。

公开(公告)号：WO2015066557A1

公开(公告)日：2015-05-07

申请号：PCT/US2014/063587

申请日：2014-10-31

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  GABEL, Chris

IPC: C12N9/22 ,  A61K38/46

CPC classification number: C12N9/22 ,  A61K38/00 ,  A61K38/465 ,  C07K14/765 ,  C07K2319/00 ,  C07K2319/31 ,  C12Y301/21001 ,  C12Y301/27005

Abstract: The invention provides for polypeptides having one or more nuclease domains (e.g., an RNase and/or DNase domain) with altered glycosylation, preferably operably coupled to a pharmacokinetic moiety, which optionally has altered glycosylation. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract translation: 本发明提供具有改变的糖基化的一个或多个核酸酶结构域（例如，RNA酶和/或DNA酶结构域）的多肽，优选可操作地偶联至药代动力学部分，其任选具有改变的糖基化。 本发明还提供了治疗或预防与异常免疫应答有关的病症的方法。

公开(公告)号：WO2015066550A1

公开(公告)日：2015-05-07

申请号：PCT/US2014/063572

申请日：2014-10-31

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  GABEL, Chris

IPC: C12N9/22 ,  A61K38/46

CPC classification number: C12N9/22 ,  A61K38/00 ,  A61K38/465 ,  C07K14/765 ,  C07K2319/00 ,  C07K2319/31 ,  C12Y301/21001 ,  C12Y301/27005

Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract translation: 本发明提供具有增加的药物动力学性质的杂交核酸酶 - 白蛋白分子。 本发明的杂交核酸酶 - 白蛋白分子具有可操作地偶联到白蛋白或其变体或片段的一个或多个核酸酶结构域（例如，RNA酶和/或DNA酶结构域）。 本发明还提供了治疗或预防与异常免疫应答有关的病症的方法。

公开(公告)号：WO2014020564A1

公开(公告)日：2014-02-06

申请号：PCT/IB2013/056321

申请日：2013-08-01

Applicant: FERRING B.V.

Inventor： HAZOUT, André

IPC: A61K38/46 ,  G01N33/68 ,  A61P15/08

CPC classification number: A61K38/465 ,  C12Q1/6883 ,  C12Y301/21001 ,  G01N33/689 ,  G06F19/22

Abstract: The present invention pertains to the use of DNase to treat female infertility and the use of cfDNA as a marker of female infertility.

Abstract translation: 本发明涉及DNase用于治疗女性不育症和使用cfDNA作为女性不育症的标志物的用途。

公开(公告)号：WO2013175172A1

公开(公告)日：2013-11-28

申请号：PCT/GB2013/051187

申请日：2013-05-08

Applicant: LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

Inventor： DAWSON, Lisa ,  WREN, Brendan

IPC: A61K38/46 ,  A61P31/04 ,  C11D3/48

CPC classification number: A61K38/465 ,  A01N43/90 ,  A61K38/482 ,  A61K45/06 ,  A61L2/16 ,  C11D3/38636 ,  C11D3/48 ,  C12Y301/21 ,  C12Y301/21001 ,  C12Y301/21002 ,  C12Y301/22001 ,  C12Y304/21064

Abstract: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonucleasefor use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonucleasefor use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease.

Abstract translation: 本发明涉及用于治疗怀疑或存在的艰难梭菌感染的脱氧核糖核酸酶; 至少含有脱氧核糖核酸酶的药物或兽药组合物或制剂，用于治疗疑似或现存的艰难梭菌感染; 包含至少脱氧核糖核酸酶用于治疗疑似或存在的艰难梭菌感染的组合治疗剂; 一种治疗怀疑被感染或受到艰难梭菌感染的哺乳动物的方法，包括至少使用脱氧核糖核酸酶; 一种清洁或消毒包含使用至少脱氧核糖核酸酶的材料或产品的方法; 和至少含有脱氧核糖核酸酶或至少含有脱氧核糖核酸酶的清洁或灭菌产品。

公开(公告)号：WO2013121228A1

公开(公告)日：2013-08-22

申请号：PCT/GB2013/050387

申请日：2013-02-18

Applicant: BIOTEC PHARMACON ASA ,  GARDNER, Rebecca

Inventor： LANES, Olav ,  HAVDALEN, Linda ,  SOLSTAD, Terese ,  LORENTZEN, Marit

IPC: C12N9/22 ,  C12N9/99 ,  C12Q1/68

CPC classification number: C12N9/22 ,  C12Q1/6806 ,  C12Q2521/301 ,  C12Y301/21001 ,  Y02A50/52

Abstract: The present invention provides an endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged as well as nucleic acid molecules encoding these enzymes and methods of removing contaminating polynucleotides from a sample using these enzyme.

Abstract translation: 本发明提供了内切核酸酶I或其酶促活性片段，其中所述内切核酸酶I具有SEQ ID No.4的序列或与其至少70％相同的序列，其中立即N末端的氨基酸残基 FYCGC五肽基序已被带负电荷的残基以及编码这些酶的核酸分子以及使用这些酶从样品中除去污染多核苷酸的方法。

公开(公告)号：WO2013114371A1

公开(公告)日：2013-08-08

申请号：PCT/IL2013/050094

申请日：2013-01-31

Applicant: PROTALIX LTD.

Inventor： SHAALTIEL, Yoseph ,  HANANIA, Uri ,  MATIUHIN, Yulia ,  FUX, Liat ,  SHULMAN, Avidor

IPC: C12N9/22

CPC classification number: A61K38/465 ,  A61K9/007 ,  A61K9/0075 ,  A61K9/14 ,  A61K33/06 ,  A61K33/14 ,  A61K38/47 ,  A61K45/06 ,  C12N9/22 ,  C12N15/8221 ,  C12N15/8257 ,  C12Y301/21001 ,  C12Y302/01052

Abstract: DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.

Abstract translation: 用于肺部给药的DNase I制剂，更具体地但非排他地，包含作为活性成分的人DNase I的方法，干粉吸入装置和用于治疗用途的系统的干粉制剂 这是提供。

公开(公告)号：WO2012166611A2

公开(公告)日：2012-12-06

申请号：PCT/US2012/039613

申请日：2012-05-25

Applicant: IMMUNE DISEASE INSTITUTE, INC. ,  WAGNER, Denisa D. ,  FUCHS, Tobias A. ,  DE MEYER, Simon ,  MARTINOD, Kimberly ,  BRILL, Alexander ,  THOMAS, Grace M.

Inventor： WAGNER, Denisa D. ,  FUCHS, Tobias A. ,  DE MEYER, Simon ,  MARTINOD, Kimberly ,  BRILL, Alexander ,  THOMAS, Grace M.

IPC: A61K38/43 ,  A61K38/46 ,  A61K31/155 ,  A61P7/00

CPC classification number: A61K38/465 ,  A61K31/155 ,  A61K31/166 ,  A61K38/49 ,  A61K39/3955 ,  A61K45/06 ,  A61M1/0209 ,  A61M1/34 ,  C12Y301/21001 ,  A61K2300/00

Abstract: Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.

Abstract translation: 本文描述的技术的实施方案基于neturophil细胞外捕获物（NETs）为血栓形成提供刺激并且NETs存在于储存的血液制品中的发现。 因此，一些实施方案涉及治疗和预防NETs的毒性和由NET引起的血栓形成的方法。 另外的实施方案涉及治疗存储的血液制品以防止输血相关损伤的方法。